EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische Studie

Effectiveness of guselkumab in patients with facial and/or genital psoriasis: Interim analysis results at Week 12 from the GULLIVER study

C Bonifati, S Lembo, A G Richetta, M Romanelli iD, F Satolli, M Corazza, L Atzori iD, C Lasagni, C Potenza, P Savoia iD, F Bardazzi, V G Di Lernia und 26 weitere

Journal of the European Academy of Dermatology and Venereology · 2025

DOI: 10.1111/jdv.20187 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2025. Verfasst von C Bonifati und 37 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Dermatology, San Gallicano Dermatological Institute, IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: Psoriasis, Antibodies, Monoclonal, Humanized, Genital Diseases, Female, Facial Dermatoses. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 55 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Facial (FP) and genital psoriasis (GP) significantly affect patients' quality of life. Despite the advances in treatments, limited data on efficacy and safety are available on these difficult‐to‐treat areas. Guselkumab is an interleukin (IL)‐23 inhibitor which has been proven effective in treating patients with moderate‐to‐severe plaque psoriasis.

Objectives

The aim of this interim analysis was to report the efficacy and safety of guselkumab in the treatment of patients with FP and/or GP. Materials and Methods GULLIVER is a 52‐week Italian observational study to evaluate the effectiveness and safety of guselkumab in a real‐life setting in patients with FP and/or GP. Adult patients with facial and/or genital moderate‐to‐severe psoriasis (sPGA score ≥ 3) were included. The primary endpoint of this analysis was the percentage of patients achieving a facial or genital sPGA score of 0 (clear) or 1 (almost clear), at Week 12. The change in the score of the facial or genital sPGA components in patients with a score ≥3 for each sPGA component was assessed. PASI score in patients with a baseline PASI above or below 10 was evaluated.

Results

Overall, 351 patients were included in the study; 83.3% of FP and 76.5% of GP patients achieved the primary endpoint. Similar response rates were observed for the facial or genital sPGA components in patients with a baseline facial or genital sPGA score ≥3 in each component. Among patients with a baseline PASI score >10, mean PASI score improved from 19.0 (SD 8.3) to 2.2 (SD 4.8). Forty‐four AEs were observed in 32 patients; two mild and transient AEs (fatigue and nausea) were considered treatment related. No SAEs were observed.

Conclusions

Guselkumab, showing to be effective and safe in treating FP and GP, may be a valid therapeutic option for patients with psoriasis localized in these difficult‐to‐treat areas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisAntibodies, Monoclonal, HumanizedGenital Diseases, FemaleFacial DermatosesGenital Diseases, MaleDermatologic AgentsHumansMaleFemaleAdultMiddle AgedTreatment OutcomeSeverity of Illness IndexAged

Substanzen

guselkumabAntibodies, Monoclonal, HumanizedDermatologic Agents

Autor:innen und Institutionen

  • Department of Clinical Dermatology, San Gallicano Dermatological Institute, IRCCS, Rome, Italy.
  • Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Salerno, Italy.
  • Unit of Dermatology, Department of Internal and Anesthetic and Cardiovascular Sciences, Sapienza University of Roma, Rome, Italy.
  • Department of Dermatology, University of Pisa, Pisa, Italy.
  • Dermatology Unit (General and Specialist Medical Department), AO - University of Parma, Parma, Italy.
  • Section of Dermatology, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.

ORCID-Profile: M Romanelli, L Atzori, P Savoia, C Guarneri, M C Fargnoli, M Burlando, S Piaserico, K Peris, A Costanzo, F Prignano, M R Bongiorno, L Stingeni, F Rongioletti, G Stinco, G Argenziano

Zitieren

APA

Bonifati, C., Lembo, S., Richetta, A. G., Romanelli, M., Satolli, F., Corazza, M., Atzori, L., Lasagni, C., Potenza, C., Savoia, P., Bardazzi, F., Di Lernia, V. G., Bianchi, L., Fabbrocini, G., Giofrè, C., Zichichi, L., Guarneri, C., Pallotta, S., Fargnoli, M. C., …, & Argenziano, G. (2025). Effectiveness of guselkumab in patients with facial and/or genital psoriasis: Interim analysis results at Week 12 from the GULLIVER study. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.20187

Vancouver

Bonifati C, Lembo S, Richetta AG, Romanelli M, Satolli F, Corazza M, et al. Effectiveness of guselkumab in patients with facial and/or genital psoriasis: Interim analysis results at Week 12 from the GULLIVER study. Journal of the European Academy of Dermatology and Venereology. 2025. doi:10.1111/jdv.20187

BibTeX
@article{Bonifati2025,
  author = {Bonifati, C and Lembo, S and Richetta, A G and Romanelli, M and Satolli, F and Corazza, M and Atzori, L and Lasagni, C and Potenza, C and Savoia, P and Bardazzi, F and Di Lernia, V G and Bianchi, L and Fabbrocini, G and Giofrè, C and Zichichi, L and Guarneri, C and Pallotta, S and Fargnoli, M C and Loconsole, F and Offidani, A and Burlando, M and Piaserico, S and Peris, K and Papini, M and Carrera, C G and Costanzo, A and Prignano, F and Bongiorno, M R and Dapavo, P and Stingeni, L and Donini, M and Micali, G and Rongioletti, F and Stinco, G and Gramiccia, T and Cantini, G and Argenziano, G},
  title = {Effectiveness of guselkumab in patients with facial and/or genital psoriasis: Interim analysis results at Week 12 from the GULLIVER study},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2025},
  doi = {10.1111/jdv.20187}
}
Kostenlos starten →